Earnings Call Summary | Bolt Biotherapeutics(BOLT.US) Q1 2024 Earnings Conference

The following is a summary of the Bolt Biotherapeutics, Inc. (BOLT) Q1 2024 Earnings Call Transcript:Financial Performance:Bolt Biotherapeutics did not provide specific financial performance data duri

Futu NewsMay 18 09:53 · Conference Call

Bolt Biotherapeutics Inc (BOLT) (Q1 2024) Earnings Call Transcript Highlights: Strategic Shifts ...

Yahoo FinanceMay 15 14:00

Bolt Biotherapeutics Cut to Market Perform From Outperform by Leerink Partners

Bolt Biotherapeutics Cut to Market Perform From Outperform by Leerink Partners

Dow JonesMay 15 12:38

Leerink Partners: Bolt Biotherapeutics (BOLT.US) rating was downgraded from superior to market unanimous rating, and target price adjusted from $3.00 to $1.00.

Leerink Partners: Bolt Biotherapeutics (BOLT.US) rating was downgraded from superior to market unanimous rating, and target price adjusted from $3.00 to $1.00.

Zhitong FinanceMay 15 12:31

Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform, Lowers Price Target to $1

Leerink Partners analyst Daina Graybosch downgrades Bolt Biotherapeutics (NASDAQ:BOLT) from Outperform to Market Perform and lowers the price target from $3 to $1.

BenzingaMay 15 12:28

NTRB, AERT and SPWR Among Mid-day Movers

Seeking AlphaMay 15 12:19